These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35578820)

  • 1. Tofacitinib for Treatment of Alopecia Areata: Real-world Evidence and Factors Associated with Therapeutic Response.
    Sanchez-Diaz M; Diaz-Calvillo P; Rodriguez-Pozo JA; Tercedor-Sánchez J; Cantudo-Cuenca MR; Molina-Leyva A; Arias-Santiago S
    Acta Derm Venereol; 2022 Jun; 102():adv00736. PubMed ID: 35578820
    [No Abstract]   [Full Text] [Related]  

  • 2. [Alopecia areata with good response to tofacitinib].
    Maksimow A; Stintzing D; Wohlrab J
    Hautarzt; 2021 Jun; 72(6):525-527. PubMed ID: 33044559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tofacitinib for the treatment of alopecia areata and variants in adolescents.
    Craiglow BG; Liu LY; King BA
    J Am Acad Dermatol; 2017 Jan; 76(1):29-32. PubMed ID: 27816292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.
    Liu LY; Craiglow BG; Dai F; King BA
    J Am Acad Dermatol; 2017 Jan; 76(1):22-28. PubMed ID: 27816293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tofacitinib therapy for children with severe alopecia areata.
    Dai YX; Chen CC
    J Am Acad Dermatol; 2019 Apr; 80(4):1164-1166. PubMed ID: 30630026
    [No Abstract]   [Full Text] [Related]  

  • 6. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
    Almutairi N; Nour TM; Hussain NH
    Dermatology; 2019; 235(2):130-136. PubMed ID: 30566941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis.
    Putterman E; Castelo-Soccio L
    J Am Acad Dermatol; 2018 Jun; 78(6):1207-1209.e1. PubMed ID: 29754888
    [No Abstract]   [Full Text] [Related]  

  • 8. Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not of Plaque Psoriasis with Tofacitinib in a Young Woman.
    Mrowietz U; Gerdes S; Gläser R; Schröder O
    Acta Derm Venereol; 2017 Feb; 97(2):283-284. PubMed ID: 27349217
    [No Abstract]   [Full Text] [Related]  

  • 9. Topical tofacitinib for the treatment of alopecia areata affecting facial hair.
    Kerkemeyer KLS; Sinclair RD; Bhoyrul B
    Br J Dermatol; 2021 Sep; 185(3):677-679. PubMed ID: 33914907
    [No Abstract]   [Full Text] [Related]  

  • 10. Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients.
    Liu LY; Craiglow BG; King BA
    J Am Acad Dermatol; 2018 Feb; 78(2):403-404.e1. PubMed ID: 29108908
    [No Abstract]   [Full Text] [Related]  

  • 11. Effectiveness and Predictive Factors of Response to Tofacitinib Therapy in 125 Patients with Alopecia Areata: A Single-centre Real-world Retrospective Study.
    Huang J; Qian P; Tang Y; Li J; Liu F; Shi W
    Acta Derm Venereol; 2023 Dec; 103():adv12425. PubMed ID: 38112208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo.
    Vu M; Heyes C; Robertson SJ; Varigos GA; Ross G
    Clin Exp Dermatol; 2017 Dec; 42(8):942-944. PubMed ID: 29034491
    [No Abstract]   [Full Text] [Related]  

  • 13. Effectiveness of oral tofacitinib treatment on patients with moderate-to-severe alopecia areata in Iran.
    Asilian A; Mohammadian P; Shahmoradi Z
    J Cosmet Dermatol; 2024 Mar; 23(3):886-890. PubMed ID: 37933534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tofacitinib for the treatment of alopecia areata in preadolescent children.
    Craiglow BG; King BA
    J Am Acad Dermatol; 2019 Feb; 80(2):568-570. PubMed ID: 30195571
    [No Abstract]   [Full Text] [Related]  

  • 15. Alopecia areata flare patterns in children and young adults while on systemic tofacitinib.
    McKenzie PL; Castelo-Soccio L
    J Am Acad Dermatol; 2022 Mar; 86(3):683-685. PubMed ID: 33667538
    [No Abstract]   [Full Text] [Related]  

  • 16. Effectiveness and safety of generic tofacitinib in alopecia areata: is the generic a cost-effective option? A retrospective study.
    Jian J; Li M; Qian P; Li J; Tang Y; Liu F; Zhao Z; Huang J; Shi W
    Arch Dermatol Res; 2024 May; 316(5):154. PubMed ID: 38734794
    [No Abstract]   [Full Text] [Related]  

  • 17. Tofacitinib therapy for alopecia areata is not associated with adverse events during COVID-19 infection.
    Youssef S; Lavian J; Lee EY; Fan W; Bordone LA
    J Am Acad Dermatol; 2023 May; 88(5):1125-1127. PubMed ID: 35551958
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical experiences on alopecia areata treatment with tofacitinib: A study of 63 patients.
    Serdaroğlu S; Engin B; Çelik U; Erkan E; Aşkın Ö; Oba Ç; Kutlubay Z
    Dermatol Ther; 2019 May; 32(3):e12844. PubMed ID: 30693634
    [No Abstract]   [Full Text] [Related]  

  • 19. Experience with oral tofacitinib in two adolescents and seven adults with alopecia areata.
    Akdogan N; Ersoy-Evans S; Doğan S; Atakan N
    Dermatol Ther; 2019 Nov; 32(6):e13118. PubMed ID: 31621150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib.
    Cheng MW; Kehl A; Worswick S; Goh C
    J Drugs Dermatol; 2018 Jul; 17(7):800-803. PubMed ID: 30005104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.